Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
Abstract Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.1%) is...
Saved in:
Main Authors: | Laura M. Periman, Darrell E. White, Douglas Katsev |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2025-01-01
|
Series: | Ophthalmology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40123-024-01076-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study
by: Swapnali Sabhapandit, et al.
Published: (2023-01-01) -
Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study
by: Sook Hyun Yoon, et al.
Published: (2025-01-01) -
He effect of cyclosporine in lambs with oral papillomatosis
by: Fahrettin Alkan, et al. -
Topical Ophthalmic Cyclosporine in the Treatment of Toxic Epidermal Necrolysis
by: Zafer Onaran, et al.
Published: (2011-01-01) -
Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation
by: Yin Zhang, et al.
Published: (2025-01-01)